ClinicalTrials.gov
public full text
Public Domain
Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
The purpose of this study is to observe correction of haemoglobin (Hb) levels in patients receiving chemotherapy as a consequence of a solid tumour, a malignant lymphoma or a multiple myeloma and who are treated with Retacrit™.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- An Observational Study of Epoetin Beta (NeoRecormon) in Participants With Cancer Receiving Chemotherapy#860402
- Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors#980461
- Biosimilar Retacrit® in the Treatment of Chemotherapy-induced Anaemia in Oncology and Haematology#1165021
- Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)#813365
- High-Dose Chemotherapy in Treating Patients Undergoing Stem Cell Transplant for Recurrent or Refractory Hodgkin's Lymphoma#992368
Record · ID 876392
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive